Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.59 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.49 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.48 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7600350 | 0.88 | RAB9A (0.66) | NPC1RAB9AKDM4EMAPTGFER | |
| SCHEMBL12763079 | 0.86 | AAK1 (0.65) | NPC1RAB9AKDM4EMAPTGFER | |
| SCHEMBL17048070 | 0.79 | NPC1 (0.54) | NPC1RAB9AKDM4EMAPTGFER | |
| SCHEMBL1519601 | 0.77 | HTR2B (0.48) | USP30AAK1ROCK2 | |
| SCHEMBL15746353 | 0.76 | NPC1 (0.52) | NPC1RAB9AKDM4EMAPTGFER | |
| SCHEMBL22091286 | 0.76 | MAPT (0.94) | NPC1RAB9AKDM4EMAPTGFER | |
| SCHEMBL15205690 | 0.75 | NPY5R (0.52) | NPC1RAB9AKDM4EMAPTGFER | |
| SCHEMBL15205692 | 0.75 | NPY5R (0.52) | NPC1RAB9AKDM4EMAPTGFER | |
| SCHEMBL27741589 | 0.75 | NPC1 (0.68) | NPC1RAB9AKDM4EMAPTGFER | |
| SCHEMBL14192726 | 0.74 | RAB9A (0.52) | NPC1RAB9AKDM4EMAPTGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038501-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. | 2015-02-05 | — | — | US | disclosed |
| US-8865756-B2 | Inhibitors of HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2014-10-21 | — | — | US | disclosed |
| US-20130296311-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-20120115855-A1 | INHIBITORS OF HCV NS5A | PRESIDIO PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296311-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | NPC1 122/4885RAB9A 1482/4885KDM4E 4113/4885 |
| US-20150038501-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | NPC1 122/4885RAB9A 1482/4885KDM4E 4113/4885 |
| US-20120115855-A1 | INHIBITORS OF HCV NS5A | HAVCR2, MAVS, EIF2AK2 | NPC1 122/4885RAB9A 1482/4885KDM4E 4113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.